Antony (France), 18 May 2011 – Stallergenes S.A. has announced that the Australian health authority, the Therapeutic Goods Administration (TGA), has approved the grass pollen sublingual immunotherapy tablet, Oralair® in adult and pediatric indications. A proven ability to build and sustain an agile sales and marketing solution is ideally suited to specialist pharmaceuticals and medical

LINK Pharma has received marketing approval in both Australia and New Zealand for “ANAPEN 500,” a 500 microgram adrenaline auto-injector. “ANAPEN 500” is approved for adults with a mean body weight of 60kg or more, or adults at high risk of severe anaphylaxis for whom a 300 microgram dose may not be sufficient. Australian and